Clinical trial
A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
NCT03411031 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 4, 2018
- Completion date
- November 4, 2021
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.